Is Hemagen Diagnostics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Hemagen Diagnostics Inc (HMGN) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Hemagen Diagnostics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hemagen Diagnostics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Hemagen Diagnostics Inc?

Muslim investors may consider investing in Hemagen Diagnostics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Hemagen Diagnostics Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Hemagen Diagnostics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Hemagen Diagnostics Inc updated?

The Shariah compliance status of Hemagen Diagnostics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Hemagen Diagnostics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Hemagen Diagnostics Inc?

You can check the latest Shariah compliance status of Hemagen Diagnostics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Hemagen Diagnostics Inc. Stock Analysis HMGN

United States Health Care Nano Cap

Hemagen Diagnostics, Inc. is a biotechnology company. The company is headquartered in Columbia, Maryland and currently employs 15 full-time employees. The firm is primarily focused on Veterinary Clinical Diagnostics. The company is also focused on VIRGO, its Human Clinical Diagnostic line of autoimmune and infectious disease products. The firm develops, manufactures and markets a range of test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. The Company’s autoimmune product portfolio includes Hemagen DNA Kit, Hemagen Rheumatoid Factor Kit, VIRGO AMA IgG, VIRGO ANA/Hep-2 IgG, VIRGO Anti-nDNA IgG, VIRGO cANCA (PR-3) Kit, VIRGO dsDNA Kit, VIRGO ENA Screen 6 Kit, VIRGO ENA Screening, VIRGO ENA Series, VIRGO pANCA myeloperoxidase (MPO) Kit and VIRGO Rheumatoid Factor Kit. The company offers various products for infectious disease, which includes VIRGO C. trach IgG, VIRGO CMV IgG and VIRGO epstein-barr virus (EBV)- viral capsid antigen (VCA) IgG. Its products are used in laboratories, hospitals and blood banks around the world.

Key Statistics of Hemagen Diagnostics Inc (HMGN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

150.00

P/E Ratio (TTM)

52 Week Range

$0.00$0.13

Market Cap

3100.00

Avg. Volume

5250.00

Dividend Yield

Financial Metrics & Statements of Hemagen Diagnostics Inc (HMGN)

FAQ's for Hemagen Diagnostics Inc (HMGN)

According to Musaffa’s Shariah screening methodology, Hemagen Diagnostics Inc (HMGN) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.